Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott N Gettinger

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 28, 2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancerStephen V Liu, D Ross Camidge, Scott N Gettinger, et al.
JTO Clinical and Research Reports|July 25, 2022
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced <i>ALK</i>-Positive NSCLCDong-Wan Kim, Shirish Gadgeel, Scott N Gettinger, et al.
Cancer|October 20, 2011
Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assayValsamo K Anagnostou, Anastasios T Dimou, Taxiarchis Botsis, et al.
Cancer|February 5, 2015
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumorsMaysa M Abu-Khalaf, Megan A Baumgart, Scott N Gettinger, et al.
Cancer Discovery|April 2, 2024
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint InhibitorsAdam J Schoenfeld, Sylvia M Lee, Bernard Doger de Spéville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403Sarah B Goldberg, Mary W Redman, Rogerio Lilenbaum, et al.
The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I studyLeora Horn, Scott N Gettinger, Michael S Gordon, et al.
Cancer Discovery|March 12, 2021
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>Giorgia Foggetti, Chuan Li, Hongchen Cai, et al.
Clinical Lung Cancer|March 22, 2021
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)Athanassios Argiris, Jieling Miao, Mihaela C Cristea, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|July 28, 2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancerStephen V Liu, D Ross Camidge, Scott N Gettinger, et al.
JTO Clinical and Research Reports|July 25, 2022
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced <i>ALK</i>-Positive NSCLCDong-Wan Kim, Shirish Gadgeel, Scott N Gettinger, et al.
Cancer|October 20, 2011
Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assayValsamo K Anagnostou, Anastasios T Dimou, Taxiarchis Botsis, et al.
Cancer|February 5, 2015
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumorsMaysa M Abu-Khalaf, Megan A Baumgart, Scott N Gettinger, et al.
Cancer Discovery|April 2, 2024
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint InhibitorsAdam J Schoenfeld, Sylvia M Lee, Bernard Doger de Spéville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403Sarah B Goldberg, Mary W Redman, Rogerio Lilenbaum, et al.
The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I studyLeora Horn, Scott N Gettinger, Michael S Gordon, et al.
Cancer Discovery|March 12, 2021
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>Giorgia Foggetti, Chuan Li, Hongchen Cai, et al.
Clinical Lung Cancer|March 22, 2021
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)Athanassios Argiris, Jieling Miao, Mihaela C Cristea, et al.
Pageof 7